Class information for:
Level 1: CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
260 3783 41.5 88%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
317 3       HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA 39408
1452 2             CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB 7818
260 1                   CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB 3783

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CHRONIC MYELOID LEUKEMIA authKW 3284437 24% 44% 922
2 IMATINIB authKW 2159194 21% 34% 785
3 NILOTINIB authKW 1527864 8% 66% 287
4 BCR ABL authKW 1363309 12% 36% 470
5 DASATINIB authKW 1327371 9% 51% 325
6 CML authKW 906150 11% 28% 400
7 IMATINIB RESISTANCE authKW 491311 2% 67% 91
8 CHRONIC MYELOGENOUS LEUKEMIA authKW 467856 6% 25% 228
9 IMATINIB MESYLATE authKW 414329 5% 27% 193
10 BCR ABL1 authKW 381001 2% 56% 85

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Hematology 86119 46% 1% 1735
2 Oncology 27084 44% 0% 1665
3 Pharmacology & Pharmacy 662 10% 0% 388
4 Medicine, Research & Experimental 266 4% 0% 164
5 Cell Biology 225 6% 0% 230
6 Medicine, General & Internal 193 5% 0% 192
7 Chemistry, Medicinal 169 3% 0% 105
8 Medical Laboratory Technology 147 1% 0% 49
9 Transplantation 60 1% 0% 47
10 Cell & Tissue Engineering 50 0% 0% 16

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 LEUKEMIA 336278 8% 13% 319
2 HEMATOL ONCOL LA SERAGNOLI 103181 1% 47% 27
3 HEMATOL 90984 20% 2% 746
4 HEMATOPOIESE LEUCEM CIBLE THER EUT 89387 0% 92% 12
5 MED UNIV KLIN 3 89263 1% 38% 29
6 HEMATOL UNIT HELSINKI 83217 1% 54% 19
7 MED FAK MANNHEIM 79540 2% 15% 64
8 PAUL OGORMAN LEUKAEMIA 69904 1% 33% 26
9 ONCOL HEMATOL CELL THER Y 64933 0% 62% 13
10 MED KLIN 3 62657 3% 6% 129

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 35566 2% 8% 58
2 LEUKEMIA 34856 5% 2% 181
3 LEUKEMIA RESEARCH 25646 4% 2% 139
4 BLOOD 24398 9% 1% 324
5 CURRENT HEMATOLOGIC MALIGNANCY REPORTS 20162 1% 9% 28
6 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 18808 2% 4% 64
7 LEUKEMIA & LYMPHOMA 18637 4% 2% 133
8 INTERNATIONAL JOURNAL OF HEMATOLOGY 17223 2% 2% 90
9 CLINICAL LYMPHOMA & MYELOMA 10979 1% 7% 21
10 ANNALS OF HEMATOLOGY 6566 1% 2% 55

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 CHRONIC MYELOID LEUKEMIA 3284437 24% 44% 922 Search CHRONIC+MYELOID+LEUKEMIA Search CHRONIC+MYELOID+LEUKEMIA
2 IMATINIB 2159194 21% 34% 785 Search IMATINIB Search IMATINIB
3 NILOTINIB 1527864 8% 66% 287 Search NILOTINIB Search NILOTINIB
4 BCR ABL 1363309 12% 36% 470 Search BCR+ABL Search BCR+ABL
5 DASATINIB 1327371 9% 51% 325 Search DASATINIB Search DASATINIB
6 CML 906150 11% 28% 400 Search CML Search CML
7 IMATINIB RESISTANCE 491311 2% 67% 91 Search IMATINIB+RESISTANCE Search IMATINIB+RESISTANCE
8 CHRONIC MYELOGENOUS LEUKEMIA 467856 6% 25% 228 Search CHRONIC+MYELOGENOUS+LEUKEMIA Search CHRONIC+MYELOGENOUS+LEUKEMIA
9 IMATINIB MESYLATE 414329 5% 27% 193 Search IMATINIB+MESYLATE Search IMATINIB+MESYLATE
10 BCR ABL1 381001 2% 56% 85 Search BCR+ABL1 Search BCR+ABL1

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 BACCARANI, M , DEININGER, MW , ROSTI, G , HOCHHAUS, A , SOVERINI, S , APPERLEY, JF , CERVANTES, F , CLARK, RE , CORTES, JE , GUILHOT, F , ET AL (2013) EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA: 2013.BLOOD. VOL. 122. ISSUE 6. P. 872 -884 129 94% 333
2 BACCARANI, M , CORTES, J , PANE, F , NIEDERWIESER, D , SAGLIO, G , APPERLEY, J , CERVANTES, F , DEININGER, M , GRATWOHL, A , GUILHOT, F , ET AL (2009) CHRONIC MYELOID LEUKEMIA: AN UPDATE OF CONCEPTS AND MANAGEMENT RECOMMENDATIONS OF EUROPEAN LEUKEMIANET.JOURNAL OF CLINICAL ONCOLOGY. VOL. 27. ISSUE 35. P. 6041-6051 106 96% 511
3 STEEGMANN, JL , BACCARANI, M , BRECCIA, M , CASADO, LF , GARCIA-GUTIERREZ, V , HOCHHAUS, A , KIM, DW , KIM, TD , KHOURY, HJ , LE COUTRE, P , ET AL (2016) EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR THE MANAGEMENT AND AVOIDANCE OF ADVERSE EVENTS OF TREATMENT IN CHRONIC MYELOID LEUKAEMIA.LEUKEMIA. VOL. 30. ISSUE 8. P. 1648 -1671 129 75% 6
4 BACCARANI, M , SAGLIO, G , GOLDMAN, J , HOCHHAUS, A , SIMONSSON, B , APPELBAUM, F , APPERLEY, J , CERVANTES, F , CORTES, J , DEININGER, M , ET AL (2006) EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF THE EUROPEAN LEUKEMIANET.BLOOD. VOL. 108. ISSUE 6. P. 1809 -1820 119 82% 539
5 O'BRIEN, S , ABBOUD, CN , AKHTARI, M , ALTMAN, J , BERMAN, E , DEANGELO, DJ , DEVINE, S , FATHI, AT , GOTLIB, J , JAGASIA, M , ET AL (2012) CHRONIC MYELOGENOUS LEUKEMIA.JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. VOL. 10. ISSUE 1. P. 64 -110 169 79% 7
6 JABBOUR, EJ , CORTES, JE , KANTARJIAN, HM , (2013) RESISTANCE TO TYROSINE KINASE INHIBITION THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA: A CLINICAL PERSPECTIVE AND EMERGING TREATMENT OPTIONS.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. VOL. 13. ISSUE 5. P. 515 -529 112 95% 23
7 DEININGER, M , BUCHDUNGER, E , DRUKER, BJ , (2005) THE DEVELOPMENT OF IMATINIB AS A THERAPEUTIC AGENT FOR CHRONIC MYELOID LEUKEMIA.BLOOD. VOL. 105. ISSUE 7. P. 2640 -2653 100 75% 708
8 APPERLEY, JF , (2015) CHRONIC MYELOID LEUKAEMIA.LANCET. VOL. 385. ISSUE 9976. P. 1447 -1459 80 84% 36
9 VALENT, P , (2008) EMERGING STEM CELL CONCEPTS FOR IMATINIB-RESISTANT CHRONIC MYELOID LEUKAEMIA: IMPLICATIONS FOR THE BIOLOGY, MANAGEMENT, AND THERAPY OF THE DISEASE.BRITISH JOURNAL OF HAEMATOLOGY. VOL. 142. ISSUE 3. P. 361 -378 142 81% 17
10 SOVERINI, S , HOCHHAUS, A , NICOLINI, FE , GRUBER, F , LANGE, T , SAGLIO, G , PANE, F , MULLER, MC , ERNST, T , ROSTI, G , ET AL (2011) BCR-ABL KINASE DOMAIN MUTATION ANALYSIS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIANET.BLOOD. VOL. 118. ISSUE 5. P. 1208-1215 78 98% 143

Classes with closest relation at Level 1


Rank Class id link
1 35514 AG 1295//BONE CANC SMYELOMA//CAREGGI UNIV HOSP INTERNAL MEDAOU CAREGGI
2 8809 CML//CHRONIC MYELOGENOUS LEUKEMIA//AUTOGRAFTING
3 9431 C ABL//BCR ABL//RIN1
4 23991 REGORAFENIB//N DESETHYL SUNITINIB//N DESMETHYL IMATINIB
5 3631 PHILADELPHIA CHROMOSOME//CANCER GENETICS AND CYTOGENETICS//BCR ABL
6 28301 ORAL CHEMOTHERAPY//ORAL ANTICANCER AGENTS//ORAL ANTICANCER DRUGS
7 15817 PRAME//LEUKEMIA ASSOCIATED ANTIGENS//PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA
8 22266 HOMOHARRINGTONINE//CEPHALOTAXINE//OMACETAXINE MEPESUCCINATE
9 9234 ACUTE LYMPHOBLASTIC LEUKEMIA//PHILADELPHIA CHROMOSOME//ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
10 10711 SRC//SRC INHIBITORS//SARACATINIB

Go to start page